In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 62, Issue 4, Pages e02542-17
Publisher
American Society for Microbiology
Online
2018-01-27
DOI
10.1128/aac.02542-17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emergence ofCandida auris: An International Call to Arms
- (2016) Cornelius J. Clancy et al. CLINICAL INFECTIOUS DISEASES
- Candidemia and invasive candidiasis in adults: A narrative review
- (2016) Spinello Antinori et al. European Journal of Internal Medicine
- Multidrug-resistant Candida auris : ‘new kid on the block’ in hospital-associated infections?
- (2016) A. Chowdhary et al. JOURNAL OF HOSPITAL INFECTION
- The anti-Aspergillusdrug pipeline: Is the glass half full or empty?: Table 1.
- (2016) Nir Osherov et al. MEDICAL MYCOLOGY
- Invasive Candidiasis
- (2015) Bart Jan Kullberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The top three areas of basic research onAspergillus fumigatusin 2011
- (2012) Nir Osherov Annals of the New York Academy of Sciences
- In VitroActivity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods
- (2011) Michael A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
- (2011) Katsura Hata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
- (2011) Mamiko Miyazaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
- (2011) Nao-aki Watanabe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
- (2011) David Andes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method
- (2011) Michael A. Pfaller et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
- (2010) D. Andes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion
- (2010) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry
- (2009) David L. Horn et al. CLINICAL INFECTIOUS DISEASES
- In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model
- (2008) D. R. Andes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started